// App-Quantinova.ai

61 : C‐BREEZE 2: Efficacy and Safety of a Two‐Drug Direct‐Acting Antiviral Agent (DAA) Regimen Ruzasvir 180 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Genotype (GT)1,2, 3, 4, or 6

Researchers

Presenter

  • Eric Lawitz

Principal Investigators

  • Edward J. Gane

  • Jordan J. Feld

  • Maria Buti

  • Graham R. Foster

  • Mordechai Rabinovitz

  • Eduard Z. Burnevich

  • Helena Katchman

  • Krzysztof Tomasiewicz

  • Frederick Lahser

  • Beth Jackson

  • Melissa Shaughnessy

  • Stephanie Klopfer

  • Wendy W. Yeh

  • Michael Robertson

  • George J. Hanna

  • Eliav Barr

  • Heather Platt

Medical Centers

  • University of Texas Health Science Center, Texas Liver Institute, San Antonio, TX

  • Auckland City Hospital, Auckland, New Zealand

  • Toronto Centre for Liver Disease, University of Toronto, Toronto, Ontario, Canada

  • Liver Unit Hospital Universitari Vall d'Hebron and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) del Instituto Carlos III Barcelona, Barcelona, Spain

  • Queen Mary University of London, London, United Kingdom

  • Division of Gastroenterology, Hepatology & Nutrition, University of Pittsburgh Medical Center, Pittsburgh, PA

  • I.M. Sechenov First Moscow State Medical University, Moscow, Russia

  • Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel

  • Merck & Co., Inc., Kenilworth, NJ

  • Medical University of Lublin, Lublin, Poland

Locations

  • United States

  • New Zealand

  • Canada

  • Spain

  • United Kingdom

  • Russia

  • Israel

  • Poland

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Hepatitis C

  • Cirrhosis

Biomarkers

  • N/A

Drug/Treatment

  • Uprifosbuvir

  • Interferon

  • Ribavirin

  • Ruzasvir

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • II

Study Id's

  • NCT02956629

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved